[
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call",
    "summary": "Charles River Laboratories’ second quarter results were met with a significant negative market reaction, despite the company’s revenue and non-GAAP profit both topping Wall Street expectations. Management attributed the quarterly outperformance primarily to stronger-than-anticipated activity in its Discovery and Safety Assessment (DSA) business, driven by bookings strength from the prior quarter and favorable foreign exchange movements. CEO James Foster highlighted stabilization in the demand en",
    "url": "https://finnhub.io/api/news?id=935055deae14680ee7e9db44ac23927862f6e9d65899cc5df5375c3d2cd620eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755063418,
      "headline": "5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call",
      "id": 136328956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River Laboratories’ second quarter results were met with a significant negative market reaction, despite the company’s revenue and non-GAAP profit both topping Wall Street expectations. Management attributed the quarterly outperformance primarily to stronger-than-anticipated activity in its Discovery and Safety Assessment (DSA) business, driven by bookings strength from the prior quarter and favorable foreign exchange movements. CEO James Foster highlighted stabilization in the demand en",
      "url": "https://finnhub.io/api/news?id=935055deae14680ee7e9db44ac23927862f6e9d65899cc5df5375c3d2cd620eb"
    }
  }
]